Hyperacute Stroke Treatment: Inclusion and Exclusion Criteria

Slides:



Advertisements
Similar presentations
GUSTO-IV AMI G lobal U se of S trategies T o Open O ccluded Coronary Arteries in AMI.
Advertisements

Stroke Workshop Case Scenario.
STROKE UPDATE Carlos S. Kase, M.D. Department of Neurology Boston Medical Center Medicine Grand Rounds New England Baptist Hospital March 17, 2011.
TPA in Stroke: What's All the Fuss?. FERNE Brain Illness and Injury Course.
1 Acute Stroke Care At the end of this study the participant will: –List 4 risk factors for stroke –Verbalize application of the Cincinnati Stroke Scale.
TPA… SMART or not SMART? That is the Question. Sarah Parker, MD.
Disclosures: Maximo C. Kiok, M.D. Medical Director of Stroke Program Trinity Health System.
STROKESTROKESTROKESTROKE. Why Change? Improve Mortality Improve Mortality Devastating and Life Altering Devastating and Life Altering Cost expense of.
The cursor must be over the text in the question boxes to have the answers open correctly.
STROKE & PREGNANCY By Judith Barnaby, Stroke CNS Reviewed by Dr. Bayer, Stroke Neurologist, St. Michael’s Hospital.
Stroke-treatment and management SAHD Naghme Adab.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
STROKE Dr Ubaid N P Community Medicine Pariyaram Medical College.
Brain Single-Photon Emission CT With HMPAO and Safety of Thrombolytic Therapy in Acute Ischemic Stroke Proceedings of the Meeting of the SPECT Safe Thrombolysis.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
TPA in Acute Ischemic Stroke: The NINDS Reanalysis & Meta-analysis Data Sidney Starkman, MD, FACEP.
T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.
Time is still Brain Victoria Parada MD Clinical Director Neuroscience and Stroke Program Valley Baptist Medical Center Harlingen Management of Acute Ischemic.
 Describe the major signs and symptoms of stroke  Classify stroke and type specific treatments  Apply 8 d’s of stroke care  Follow suspected stroke.
FERNE/MEMC Session: Treating Ischemic Stroke in the 3 – 4
Edward P. Sloan, MD, MPH FERNE/EMA Session: Treating Ischemic Stroke Patients Using a 3 to 4.5 Hour tPA Window.
Acute ischemic stroke: Not a moment to lose By Julie Miller, RN, CCRN, BSN, & Janice Mink, RN, CCRN, CNRN Nursing2009, May ANCC contact hours.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
T. P.A. tissue Plasminogen Activator Presented by: Kelly Banasky, RN, BSN GCH Emergency Services Educator.
The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Brief Protocol Training NIH-NINDS U01 NS NETT CCC U01 NS NETT SDMC U01 NS
Stroke and the ED Kurian Thomas, MD Department of Neurology.
New Treatment Advances in Acute Coronary Syndrome.
The Evolving Management of Pediatric Stroke Christopher A. Miller, MD July 21, 2012.
10 May 2005 CASES - Original article available at CASES (Canadian Alteplase for Stroke Effectiveness Study) The CASES Investigators.
S TPA and Appropriate documentation for contraindications: A conversation with The Joint Commission and a Physician Perspective Shyam Prabhakaran, MD,
Evidence in the ED Byron Drumheller, MD Penn Emergency Medicine.
The ASSENT 3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT 3 randomised.
Treatment of Ischaemic Stroke The American Heart Association American Stroke Association Guidelines Stroke. 2007;38:
Delayed Posttraumatic Hemorrhage From (Stroke. 1995;26: ) © 1995 American Heart Association, Inc. Present by R2 Meng-Ting Wu.
STROKE Lalith Sivanathan 2015 ADVANCED CONCEPTS IN EMERGENCY CARE (EMS 483)
Subarachnoid Hemorrhage. Etiology Spontaneous (primary) subarachnoid hemorrhage usually results from ruptured aneurysms. A congenital intracranial saccular.
Chapter 31 Stroke. © 2005 by Thomson Delmar Learning,a part of The Thomson Corporation. All Rights Reserved 2 Overview  Pathophysiology  Types of Stroke.
Intracerebral Hemorrhage
Stroke : To Lyse or Not to Lyse ? Understand the Literature and Decide : What is best for your practice environment ?
Behavioral Objectives  To make the student define the stroke.  To make the student learn the types of stroke.  To make the student Know who are the.
Primary Stroke Center EMS Training Union Hospital, Inc. Terre Haute Union Hospital, Inc. Terre Haute.
Jennifer Williams, PhD, RN, ACNS-BC Clinical Nurse Specialist Emergency Services Barnes-Jewish Hospital Acute Stroke Management and Interventions 2016.
Dr Payam Sasannejad, Neurologist Assistant Professor of mums Intravenous thrombolytic therapy in acute ischemic stroke.
Rikki Weems, PGY III August 20, 2015
“Door to Needle (DTN) Time in Stroke Thrombolysis” Audit Care of the Elderly Department Dr Nikoletta Petrou, Foundation Year 1 Doctor Dr Prasanna Aghoram,
Stroke Rami Unterman, M.D.. Objectives Define and differentiate the types of stroke Recognize the urgency involved in the evaluation and management of.
Simon Howard Medical Management of Acute Stroke. Fast Recognition of Stroke With sudden onset neurological symptoms: 'FAST' should be used to screen for.
ACUTE STROKE TREATMENT: An introduction Dec.2014
Chapter 35 Stroke. Stroke: occurs when blood flow to the brain is interrupted by a clot in a artery or other vessel. When this occur brain cells begin.
Stroke Protocol Time Lost Is Brain Lost!. Objective: Improve patient care & outcomes Offer a standard of care Increase efficiency Meet accreditation recommendations.
Inclusion/exclusion criteria and decision making on thrombolysis treatment in stroke. Dr Anthony Pereira Department of Neurology St George’s Hospital.
Adult Stroke 2010 AHA Guidelines for CPR and ECC
Management of Acute ISCHEMIC stroke
Acute Ischemic Stroke: Introduction to Diagnosis and Treatment
Advances in Treatment for Acute Stroke
ACLS CVA.
Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.
Rapid Reversal of Warfarin Therapy in Patients with Intracranial / Intraspinal Bleeding Mount Auburn Hospital Blood Bank, Emergency Department, Critical.
Acute Stroke Therapy with IV Thrombolysis Lawrence R. Wechsler, M.D.
When Not to Intervene in Acute Stroke or
Chiara Franchini, Anne Bruton , Cathy Limby Stroke Specialist Nurses
Stroke Niazy B Hussam.
Intern Morning Report July 2014 Tram Le, PGY3
Performance Improvement: Emergency Management in Acute Cerebrovascular Patients Current US Guidelines Lisa A. Shultz, MD Medical Director, Lourdes Stroke.
Updates in the Treatment of Acute Stroke
Approach to Hemorrhagic and Ischemic Strokes
Strokes.
TIA/Stroke (1) C.L.I.P.S. Why do we care?
Extended Window Thrombectomy
The Multi-arm Optimization of Stroke Thrombolysis (MOST) Trial
Presentation transcript:

Hyperacute Stroke Treatment: Inclusion and Exclusion Criteria

T-PA Benefit Odds ratio of favorable outcome if t-PA is given: within 90 min of symptom onset= 2.81 (95% CI, 1.75-4.50) Within 90 and 180 min of symptom onset= 1.55 (95% CI, 1.12-2.15) Community registry study SITS-ISTR: frequency of favorable outcome is 56.3% (CI, 55.3-57%)

T-PA Benefit 3 to 4.5 hour Odds ratio of excellent outcome= 1.40 (95% CI, 1.05-1.85) ECASS III trial odds ratio mRS 0-1: odds ratio 1.34 (95% CI, 1.02- 1.76)

T-pa Risk Major risk is intracerebral hemorrhage with variable rates of occurrence 1.9% to 10% Risk of hemorrhage increases in proportion to degree to which the protocol is not followed Angioedema estimated to occur between 1.3 – 5.1% More associated with angiotensin converting enzyme inhibitor use Infarct involving the insular and frontal cortex

Inclusion Criteria for Intravenous t-PA Diagnosis of ischemic stroke causing measurable neurological deficit Onset of symptoms < 3hours before beginning treatment Onset time is defined as either the witnessed onset of symptoms or the time last known normal if symptom onset was not witnessed Aged > 18 years

Exclusion Criteria for Intravenous t-PA Significant head trauma or prior stroke in previous 3 months Small stroke within 3 months may be considered but should be included in risk discussion with patient or family member Symptoms suggest subarachnoid hemorrhage Arterial puncture at a noncompressible site in previous 7 days

Exclusion Criteria for Intravenous t-PA History of previous intracerebral hemorrhage Intracranial neoplasm, arteriovenous malformation, aneurysm Recent intracranial or intraspinal surgery Elevated blood pressure (systolic >185 or diastolic >110mm Hg)

Exclusion Criteria for Intravenous t-PA Active internal bleeding Acute bleeding diathesis, including but not limited to: Platelet count < 100,00/mm Heparin received within 48 hours, resulting in abnormally elevated aPTT greater than the upper limit of normal Current use of anticoagulant wit INR>1.7 or PT>15 seconds Current use of direct thrombin inhibitors or direct factor Xa inhibitors with elevatd sensitive laboratory tests(i.e. aPTT, INR, ECT, TT, or appropriate factor Xa activity assays

Exclusion Criteria for Intravenous t-PA Blood glucose concentration <50 mg/dl Can correct and reassess patient NIHSS CT demonstrates multilobar infarction (hypodensity> 1/3 cerebral hemisphere

Relative Exclusion Criteria for Intravenous t-PA Only minor or rapidly improving symptoms (clearing spontaneously) Pregnancy Seizure at onset with postictal residula neurological impairments Major surgery or serious trauma within past 14 days Recent gastrointestinal or urinary tract hemorrhage (within past 21 days) Recent acute myocardial infarction (within previous 3 months)

Relative Exclusion Criteria for Intravenous t-PA Under some circumstances– with careful consideration and weighing of risk to benefit– patients may receive t-PA despite 1 or more relative contraindications.

Relative Exclusion Criteria for Intravenous t-PA Patients without recent use of oral anticoagulants or heparin, treatment with t-PA can be initiated before coagulation test results are back. Discontinue t-PA if exclusion criteria are met. Patients without a history of thrombocytopenia, treatment with t-PA can be initiated before platelet count is back. Discontinue t-PA if exclusion criteria are met.

Additional Inclusion Criteria for Intravenous t-PA use between 3 and 4 Additional Inclusion Criteria for Intravenous t-PA use between 3 and 4.5 hours Diagnosis of ischemic stroke causing a measurable neurological deficit Symptom onset within 3 to 4.5 hours before beginning treatment

Additional Relative Exclusion For t-PA administration within 3 to 4 Additional Relative Exclusion For t-PA administration within 3 to 4.5 hours Aged >80 years Severe Stroke (NIHSS> 25) Taking an oral anticoagulant regardless of INR History of both diabetes and prior ischemic stroke

Warning Signs for Significant Hemorrhagic Transformation Sudden onset of severe headache Acute hypertension Acute nausea or vomiting Worsening neurological exam Discontinue t-PA infusion and obtain stat CT non-contrast of brain Restart infusion if no bleed

Conclusions Ischemic Stroke: Get a complete history and present history succinctly and accurately to tele-neurologist Alert tele-neurologist of any concerns with regard to patient care or t-PA administration Keep Communication Lines Open